7Baggers

Allakos Inc
(NASDAQ:ALLK) 

ALLK stock logo

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic es...

Founded: 2012
Full Time Employees: 114
CEO: Robert D. Alexander Ph.D.  
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2024-03-31 
     
      operating expenses
    		 
      research and development
    		34,824,000 
      general and administrative
    		10,898,000 
      impairment of long-lived assets
    		27,347,000 
      total operating expenses
    		73,069,000 
      income from operations
    		-73,069,000 
      yoy
    		 
      qoq
    		 
      interest income
    		1,995,000 
      other income
    		-72,000 
      net income
    		-71,146,000 
      yoy
    		 
      qoq
    		 
      unrealized gain on investments
    		-30,000 
      comprehensive loss
    		-71,176,000 
      net income per common share:
    		 
      basic and diluted
    		-810 
      weighted-average number of common shares outstanding:
    		 
      basic and diluted
    		88,042,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2024-03-31 
       
        assets
      		 
        current assets:
      		 
        cash and cash equivalents
      		43,060,000 
        investments
      		96,192,000 
        prepaid expenses and other current assets
      		8,382,000 
        total current assets
      		147,634,000 
        property and equipment
      		17,364,000 
        operating lease right-of-use assets
      		10,577,000 
        other long-term assets
      		1,737,000 
        total assets
      		177,312,000 
        liabilities and stockholders’ equity
      		 
        current liabilities:
      		 
        accounts payable
      		15,748,000 
        accrued expenses and other current liabilities
      		20,173,000 
        total current liabilities
      		35,921,000 
        operating lease liabilities, net of current portion
      		37,408,000 
        total liabilities
      		73,329,000 
        contingencies
      		 
        stockholders’ equity:
      		 
        preferred stock, 0.001 par value per share...
      		 
        common stock, 0.001 par value per share...
      		89,000 
        additional paid-in capital
      		1,293,497,000 
        accumulated other comprehensive gain
      		20,000 
        accumulated deficit
      		-1,189,623,000 
        total stockholders’ equity
      		103,983,000 
        total liabilities and stockholders’ equity
      		177,312,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2024-03-31 
         
          cash flows from operating activities
        		 
          net income
        		-71,146,000 
          adjustments to reconcile net income to net cash from operating activities:
        		 
          impairment of long-lived assets
        		27,347,000 
          depreciation and amortization
        		1,072,000 
          stock-based compensation
        		6,210,000 
          net accretion of premiums and discounts on investments
        		-962,000 
          noncash lease expense
        		1,149,000 
          changes in operating assets and liabilities:
        		 
          prepaid expenses and other current assets
        		774,000 
          other long-term assets
        		4,479,000 
          accounts payable
        		13,984,000 
          accrued expenses and other current liabilities
        		-14,641,000 
          operating lease liabilities, net of current portion
        		-807,000 
          net cash from operating activities
        		-32,541,000 
          capital expenditures
        		-4,000 
          free cash flows
        		-32,545,000 
          cash flows from investing activities
        		 
          purchases of investments
        		-34,367,000 
          proceeds from maturities of investments
        		43,400,000 
          purchases of property and equipment
        		-4,000 
          net cash from investing activities
        		9,029,000 
          cash flows from financing activities
        		 
          proceeds from issuance of common stock, net of issuance costs
        		 
          proceeds from exercise of stock options
        		26,000 
          proceeds from issuance of common stock under the 2018 espp
        		106,000 
          net cash from financing activities
        		132,000 
          net increase in cash, cash equivalents and restricted cash
        		-23,380,000 
          cash, cash equivalents and restricted cash, beginning of period
        		67,912,000 
          cash, cash equivalents and restricted cash, end of period
        		44,532,000 
          supplemental disclosures
        		 
          noncash investing and financing items:
        		 
          noncash adjustments to right-of-use assets upon lease amendment